{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:18:11Z","timestamp":1794028691648,"version":"4.8.0"},"reference-count":346,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Investigations of apolipoprotein E (<jats:italic>APOE<\/jats:italic>) gene, the major genetic risk modifier for Alzheimer\u2019s disease (AD), have yielded significant insights into the pathogenic mechanism. Among the three common coding variants,<jats:italic>APOE*\u03b54<\/jats:italic>increases, whereas<jats:italic>APOE*\u03b52<\/jats:italic>decreases the risk of late-onset AD compared with<jats:italic>APOE*\u03b53<\/jats:italic>. Despite increased understanding of the detrimental effect of<jats:italic>APOE*\u03b54<\/jats:italic>, it remains unclear how<jats:italic>APOE*\u03b52<\/jats:italic>confers protection against AD. Accumulating evidence suggests that<jats:italic>APOE*\u03b52<\/jats:italic>protects against AD through both amyloid-\u03b2 (A\u03b2)-dependent and independent mechanisms. In addition,<jats:italic>APOE*\u03b52<\/jats:italic>has been identified as a longevity gene, suggesting a systemic effect of<jats:italic>APOE*\u03b52<\/jats:italic>on the aging process. However,<jats:italic>APOE*\u03b52<\/jats:italic>is not entirely benign;<jats:italic>APOE*\u03b52<\/jats:italic>carriers exhibit increased risk of certain cerebrovascular diseases and neurological disorders. Here, we review evidence from both human and animal studies demonstrating the protective effect of<jats:italic>APOE*\u03b52<\/jats:italic>against AD and propose a working model depicting potential underlying mechanisms. Finally, we discuss potential therapeutic strategies designed to leverage the protective effect of<jats:italic>APOE2<\/jats:italic>to treat AD.<\/jats:p>","DOI":"10.1186\/s13024-020-00413-4","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T09:08:39Z","timestamp":1604480919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":282,"title":["APOE2: protective mechanism and therapeutic implications for Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-9608","authenticated-orcid":false,"given":"Zonghua","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1659-1952","authenticated-orcid":false,"given":"Francis","family":"Shue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8648-9422","authenticated-orcid":false,"given":"Na","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3045-7338","authenticated-orcid":false,"given":"Mitsuru","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3491-1016","authenticated-orcid":false,"given":"Guojun","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"issue":"5","key":"413_CR1","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.neuron.2019.01.056","volume":"101","author":"ME Belloy","year":"2019","unstructured":"Belloy ME, Napolioni V, Greicius MD. A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. Neuron. 2019;101(5):820\u201338.","journal-title":"Neuron"},{"issue":"4","key":"413_CR2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.biopsych.2017.03.003","volume":"83","author":"N Zhao","year":"2018","unstructured":"Zhao N, et al. Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease. Biol Psychiatry. 2018;83(4):347\u201357.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"413_CR3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13024-020-00391-7","volume":"15","author":"T Guo","year":"2020","unstructured":"Guo T, et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. Mol Neurodegener. 2020;15(1):40.","journal-title":"Mol Neurodegener"},{"issue":"9","key":"413_CR4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki Y, et al. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15(9):501\u201318.","journal-title":"Nat Rev Neurol"},{"issue":"16","key":"413_CR5","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer LA, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama. 1997;278(16):1349\u201356.","journal-title":"Jama"},{"issue":"9","key":"413_CR6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/mp.2011.52","volume":"16","author":"E Genin","year":"2011","unstructured":"Genin E, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry. 2011;16(9):903\u20137.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"413_CR7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/0306-4522(95)00331-C","volume":"69","author":"Z Nagy","year":"1995","unstructured":"Nagy Z, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience. 1995;69(3):757\u201361.","journal-title":"Neuroscience"},{"issue":"17","key":"413_CR8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/WNL.0b013e3181a2e87d","volume":"72","author":"DA Bennett","year":"2009","unstructured":"Bennett DA, et al. Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. Neurology. 2009;72(17):1495\u2013503.","journal-title":"Neurology"},{"issue":"6","key":"413_CR9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/ana.24369","volume":"77","author":"A Serrano-Pozo","year":"2015","unstructured":"Serrano-Pozo A, et al. APOEepsilon2 is associated with milder clinical and pathological Alzheimer disease. Ann Neurol. 2015;77(6):917\u201329.","journal-title":"Ann Neurol"},{"issue":"1","key":"413_CR10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman EM, et al. Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun. 2020;11(1):667.","journal-title":"Nat Commun"},{"issue":"19","key":"413_CR11","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924\u201338.","journal-title":"JAMA"},{"issue":"5","key":"413_CR12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ana.24628","volume":"79","author":"M Shinohara","year":"2016","unstructured":"Shinohara M, et al. APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations. Ann Neurol. 2016;79(5):758\u201374.","journal-title":"Ann Neurol"},{"issue":"9","key":"413_CR13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1212\/01.wnl.0000343853.00346.a4","volume":"72","author":"DJ Berlau","year":"2009","unstructured":"Berlau DJ, et al. APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology. 2009;72(9):829\u201334.","journal-title":"Neurology"},{"issue":"8","key":"413_CR14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1001\/archneur.64.8.1193","volume":"64","author":"DJ Berlau","year":"2007","unstructured":"Berlau DJ, et al. Dissociation of neuropathologic findings and cognition: case report of an apolipoprotein E epsilon2\/epsilon2 genotype. Arch Neurol. 2007;64(8):1193\u20136.","journal-title":"Arch Neurol"},{"issue":"1","key":"413_CR15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1471-4159.2004.03007.x","volume":"93","author":"HS Hoe","year":"2005","unstructured":"Hoe HS, Harris DC, Rebeck GW. Multiple pathways of apolipoprotein E signaling in primary neurons. J Neurochem. 2005;93(1):145\u201355.","journal-title":"J Neurochem"},{"issue":"8","key":"413_CR16","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1523\/JNEUROSCI.5471-06.2007","volume":"27","author":"H Hayashi","year":"2007","unstructured":"Hayashi H, et al. Apolipoprotein E-containing lipoproteins protect neurons from apoptosis via a signaling pathway involving low-density lipoprotein receptor-related protein-1. J Neurosci. 2007;27(8):1933\u201341.","journal-title":"J Neurosci"},{"issue":"37","key":"413_CR17","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1523\/JNEUROSCI.2994-18.2019","volume":"39","author":"YA Huang","year":"2019","unstructured":"Huang YA, et al. Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk. J Neurosci. 2019;39(37):7408\u201327.","journal-title":"J Neurosci"},{"issue":"26","key":"413_CR18","doi-asserted-by":"crossref","first-page":"12011","DOI":"10.1073\/pnas.0914984107","volume":"107","author":"Y Chen","year":"2010","unstructured":"Chen Y, et al. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci U S A. 2010;107(26):12011\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"413_CR19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1474-9726.2011.00705.x","volume":"10","author":"J Deelen","year":"2011","unstructured":"Deelen J, et al. Genome-wide association study identifies a single major locus contributing to survival into old age; the APOE locus revisited. Aging Cell. 2011;10(4):686\u201398.","journal-title":"Aging Cell"},{"issue":"6-7","key":"413_CR20","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.mad.2011.06.008","volume":"132","author":"A Nebel","year":"2011","unstructured":"Nebel A, et al. A genome-wide association study confirms APOE as the major gene influencing survival in long-lived individuals. Mech Ageing Dev. 2011;132(6-7):324\u201330.","journal-title":"Mech Ageing Dev"},{"issue":"1","key":"413_CR21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029848","volume":"7","author":"P Sebastiani","year":"2012","unstructured":"Sebastiani P, et al. Genetic signatures of exceptional longevity in humans. PLoS One. 2012;7(1):e29848.","journal-title":"PLoS One"},{"issue":"16","key":"413_CR22","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1093\/hmg\/ddu139","volume":"23","author":"J Deelen","year":"2014","unstructured":"Deelen J, et al. Genome-wide association meta-analysis of human longevity identifies a novel locus conferring survival beyond 90 years of age. Hum Mol Genet. 2014;23(16):4420\u201332.","journal-title":"Hum Mol Genet"},{"key":"413_CR23","doi-asserted-by":"crossref","first-page":"21243","DOI":"10.1038\/srep21243","volume":"6","author":"Y Zeng","year":"2016","unstructured":"Zeng Y, et al. Novel loci and pathways significantly associated with longevity. Sci Rep. 2016;6:21243.","journal-title":"Sci Rep"},{"issue":"5","key":"413_CR24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/archneur.1996.00550050048022","volume":"53","author":"EH Corder","year":"1996","unstructured":"Corder EH, et al. Apolipoprotein E genotype determines survival in the oldest old (85 years or older) who have good cognition. Arch Neurol. 1996;53(5):418\u201322.","journal-title":"Arch Neurol"},{"issue":"10","key":"413_CR25","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.neurobiolaging.2007.12.003","volume":"30","author":"L Rosvall","year":"2009","unstructured":"Rosvall L, et al. APOE-related mortality: effect of dementia, cardiovascular disease and gender. Neurobiol Aging. 2009;30(10):1545\u201351.","journal-title":"Neurobiol Aging"},{"issue":"7","key":"413_CR26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/NEN.0b013e31829a25b9","volume":"72","author":"PT Nelson","year":"2013","unstructured":"Nelson PT, et al. APOE-epsilon2 and APOE-epsilon4 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol. 2013;72(7):708\u201315.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"11","key":"413_CR27","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.neurobiolaging.2015.08.008","volume":"36","author":"L Yu","year":"2015","unstructured":"Yu L, et al. APOE and cerebral amyloid angiopathy in community-dwelling older persons. Neurobiol Aging. 2015;36(11):2946\u201353.","journal-title":"Neurobiol Aging"},{"issue":"12","key":"413_CR28","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/da.22138","volume":"30","author":"TY Kim","year":"2013","unstructured":"Kim TY, et al. Apolipoprotein E gene polymorphism, alcohol use, and their interactions in combat-related posttraumatic stress disorder. Depress Anxiety. 2013;30(12):1194\u2013201.","journal-title":"Depress Anxiety"},{"issue":"12","key":"413_CR29","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/humu.21577","volume":"32","author":"GJ McKay","year":"2011","unstructured":"McKay GJ, et al. Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies. Hum Mutat. 2011;32(12):1407\u201316.","journal-title":"Hum Mutat"},{"issue":"1","key":"413_CR30","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1038\/s41467-018-06783-0","volume":"9","author":"N Zhao","year":"2018","unstructured":"Zhao N, et al. APOE \u03b52 is associated with increased tau pathology in primary tauopathy. Nat Commun. 2018;9(1):4388.","journal-title":"Nat Commun"},{"issue":"3","key":"413_CR31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s004010050886","volume":"96","author":"E Ghebremedhin","year":"1998","unstructured":"Ghebremedhin E, et al. Argyrophilic grain disease is associated with apolipoprotein E epsilon 2 allele. Acta Neuropathol. 1998;96(3):222\u20134.","journal-title":"Acta Neuropathol"},{"issue":"8","key":"413_CR32","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1016\/S0021-9258(18)34702-1","volume":"257","author":"SC Rall","year":"1982","unstructured":"Rall SC, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem. 1982;257(8):4171\u20138.","journal-title":"J Biol Chem"},{"issue":"10","key":"413_CR33","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1016\/S0021-9258(18)88963-3","volume":"260","author":"HK Das","year":"1985","unstructured":"Das HK, et al. Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. J Biol Chem. 1985;260(10):6240\u20137.","journal-title":"J Biol Chem"},{"issue":"17","key":"413_CR34","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1016\/S0021-9258(19)52510-8","volume":"256","author":"KH Weisgraber","year":"1981","unstructured":"Weisgraber KH, Rall SC, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 1981;256(17):9077\u201383.","journal-title":"J Biol Chem"},{"issue":"13","key":"413_CR35","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1016\/S0021-9258(18)68778-2","volume":"263","author":"JR Wetterau","year":"1988","unstructured":"Wetterau JR, et al. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. J Biol Chem. 1988;263(13):6240\u20138.","journal-title":"J Biol Chem"},{"key":"413_CR36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0065-3233(08)60642-7","volume":"45","author":"KH Weisgraber","year":"1994","unstructured":"Weisgraber KH. Apolipoprotein E: structure-function relationships. Adv Protein Chem. 1994;45:249\u2013302.","journal-title":"Adv Protein Chem"},{"issue":"13","key":"413_CR37","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.1016\/S0021-9258(18)68779-4","volume":"263","author":"LP Aggerbeck","year":"1988","unstructured":"Aggerbeck LP, et al. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem. 1988;263(13):6249\u201358.","journal-title":"J Biol Chem"},{"issue":"15","key":"413_CR38","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1523\/JNEUROSCI.17-15-05678.1997","volume":"17","author":"M Tolar","year":"1997","unstructured":"Tolar M, et al. Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J Neurosci. 1997;17(15):5678\u201386.","journal-title":"J Neurosci"},{"issue":"8","key":"413_CR39","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/S0021-9258(18)68957-4","volume":"263","author":"A Lalazar","year":"1988","unstructured":"Lalazar A, et al. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J Biol Chem. 1988;263(8):3542\u20135.","journal-title":"J Biol Chem"},{"issue":"35","key":"413_CR40","doi-asserted-by":"crossref","first-page":"22358","DOI":"10.1016\/S0021-9258(17)31797-0","volume":"269","author":"LM Dong","year":"1994","unstructured":"Dong LM, et al. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem. 1994;269(35):22358\u201365.","journal-title":"J Biol Chem"},{"issue":"17","key":"413_CR41","doi-asserted-by":"crossref","first-page":"14782","DOI":"10.1074\/jbc.M213207200","volume":"278","author":"H Saito","year":"2003","unstructured":"Saito H, et al. Characterization of the heparin binding sites in human apolipoprotein E. J Biol Chem. 2003;278(17):14782\u20137.","journal-title":"J Biol Chem"},{"issue":"7","key":"413_CR42","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1074\/jbc.M411719200","volume":"280","author":"M Futamura","year":"2005","unstructured":"Futamura M, et al. Two-step mechanism of binding of apolipoprotein E to heparin: implications for the kinetics of apolipoprotein E-heparan sulfate proteoglycan complex formation on cell surfaces. J Biol Chem. 2005;280(7):5414\u201322.","journal-title":"J Biol Chem"},{"issue":"1","key":"413_CR43","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1172\/JCI115288","volume":"88","author":"MF Linton","year":"1991","unstructured":"Linton MF, et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest. 1991;88(1):270\u201381.","journal-title":"J Clin Invest"},{"issue":"1","key":"413_CR44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1073\/pnas.82.1.203","volume":"82","author":"NA Elshourbagy","year":"1985","unstructured":"Elshourbagy NA, et al. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci U S A. 1985;82(1):203\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"413_CR45","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1523\/JNEUROSCI.5476-05.2006","volume":"26","author":"Q Xu","year":"2006","unstructured":"Xu Q, et al. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J Neurosci. 2006;26(19):4985\u201394.","journal-title":"J Neurosci"},{"key":"413_CR46","doi-asserted-by":"crossref","unstructured":"Huynh T-V, et al. Lack of hepatic apoE does not influence early A\u03b2 deposition: observations from a new APOE knock-in model. Mol Neurodegener. 2019;14(1):37.","DOI":"10.1186\/s13024-019-0337-1"},{"issue":"3","key":"413_CR47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00005072-199903000-00002","volume":"58","author":"K Horsburgh","year":"1999","unstructured":"Horsburgh K, et al. Influence of apolipoprotein E genotype on neuronal damage and apoE immunoreactivity in human hippocampus following global ischemia. J Neuropathol Exp Neurol. 1999;58(3):227\u201334.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"20","key":"413_CR48","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1093\/hmg\/dds296","volume":"21","author":"C Cruchaga","year":"2012","unstructured":"Cruchaga C, et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum Mol Genet. 2012;21(20):4558\u201371.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"413_CR49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ije\/dyt034","volume":"42","author":"TA Khan","year":"2013","unstructured":"Khan TA, et al. Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. Int J Epidemiol. 2013;42(2):475\u201392.","journal-title":"Int J Epidemiol"},{"key":"413_CR50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.euprot.2015.07.012","volume":"8","author":"M Rezeli","year":"2015","unstructured":"Rezeli M, et al. Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer\u2019s disease and other neurodegenerative diseases. EuPA Open Proteomics. 2015;8:137\u201343.","journal-title":"EuPA Open Proteomics"},{"issue":"4","key":"413_CR51","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jacl.2016.03.003","volume":"10","author":"JP Corsetti","year":"2016","unstructured":"Corsetti JP, et al. Apolipoprotein E levels and apolipoprotein E genotypes in incident cardiovascular disease risk in subjects of the Prevention of Renal and Vascular End-stage disease study. J Clin Lipidol. 2016;10(4):842\u201350.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"413_CR52","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00401-014-1266-2","volume":"127","author":"E Mart\u00ednez-Morillo","year":"2014","unstructured":"Mart\u00ednez-Morillo E, et al. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Acta Neuropathol. 2014;127(5):633\u201343.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"413_CR53","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13195-020-00585-7","volume":"12","author":"K Minta","year":"2020","unstructured":"Minta K, et al. Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. Alzheimers Res Ther. 2020;12(1):19.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"413_CR54","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/mp.2013.194","volume":"19","author":"C Conejero-Goldberg","year":"2014","unstructured":"Conejero-Goldberg C, et al. APOE2 enhances neuroprotection against Alzheimer's disease through multiple molecular mechanisms. Mol Psychiatry. 2014;19(11):1243\u201350.","journal-title":"Mol Psychiatry"},{"issue":"11","key":"413_CR55","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1172\/JCI6172","volume":"103","author":"C Knouff","year":"1999","unstructured":"Knouff C, et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest. 1999;103(11):1579\u201386.","journal-title":"J Clin Invest"},{"issue":"46","key":"413_CR56","doi-asserted-by":"crossref","first-page":"10658","DOI":"10.1523\/JNEUROSCI.1922-05.2005","volume":"25","author":"G Ramaswamy","year":"2005","unstructured":"Ramaswamy G, et al. Effect of domain interaction on apolipoprotein E levels in mouse brain. J Neurosci. 2005;25(46):10658\u201363.","journal-title":"J Neurosci"},{"issue":"45","key":"413_CR57","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1523\/JNEUROSCI.1972-08.2008","volume":"28","author":"DR Riddell","year":"2008","unstructured":"Riddell DR, et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci. 2008;28(45):11445\u201353.","journal-title":"J Neurosci"},{"key":"413_CR58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1326-8-13","volume":"8","author":"JD Ulrich","year":"2013","unstructured":"Ulrich JD, et al. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener. 2013;8:13.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"413_CR59","doi-asserted-by":"crossref","first-page":"a006312","DOI":"10.1101\/cshperspect.a006312","volume":"2","author":"DM Holtzman","year":"2012","unstructured":"Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(3):a006312.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"413_CR60","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tem.2016.12.001","volume":"28","author":"C Lane-Donovan","year":"2017","unstructured":"Lane-Donovan C, Herz J. ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease. Trends Endocrinol Metab. 2017;28(4):273\u201384.","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"413_CR61","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrn2620","volume":"10","author":"G Bu","year":"2009","unstructured":"Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10(5):333\u201344.","journal-title":"Nat Rev Neurosci"},{"issue":"43","key":"413_CR62","doi-asserted-by":"crossref","first-page":"26043","DOI":"10.1074\/jbc.M115.679043","volume":"290","author":"Y Atagi","year":"2015","unstructured":"Atagi Y, et al. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J Biol Chem. 2015;290(43):26043\u201350.","journal-title":"J Biol Chem"},{"issue":"43","key":"413_CR63","doi-asserted-by":"crossref","first-page":"26033","DOI":"10.1074\/jbc.M115.677286","volume":"290","author":"CC Bailey","year":"2015","unstructured":"Bailey CC, DeVaux LB, Farzan M. The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E. J Biol Chem. 2015;290(43):26033\u201342.","journal-title":"J Biol Chem"},{"issue":"2","key":"413_CR64","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.neuron.2016.06.015","volume":"91","author":"FL Yeh","year":"2016","unstructured":"Yeh FL, et al. TREM2 Binds to Apolipoproteins, Including APOE and CLU\/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron. 2016;91(2):328\u201340.","journal-title":"Neuron"},{"issue":"5","key":"413_CR65","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/S0021-9258(18)34954-8","volume":"257","author":"KH Weisgraber","year":"1982","unstructured":"Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982;257(5):2518\u201321.","journal-title":"J Biol Chem"},{"issue":"11","key":"413_CR66","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1016\/S0021-9258(17)39866-6","volume":"259","author":"TL Innerarity","year":"1984","unstructured":"Innerarity TL, et al. Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation. J Biol Chem. 1984;259(11):7261\u20137.","journal-title":"J Biol Chem"},{"issue":"8","key":"413_CR67","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1194\/jlr.M500114-JLR200","volume":"46","author":"J Ruiz","year":"2005","unstructured":"Ruiz J, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res. 2005;46(8):1721\u201331.","journal-title":"J Lipid Res"},{"issue":"24","key":"413_CR68","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1073\/pnas.1705080114","volume":"114","author":"C Frieden","year":"2017","unstructured":"Frieden C, Wang H, Ho CMW. A mechanism for lipid binding to apoE and the role of intrinsically disordered regions coupled to domain-domain interactions. Proc Natl Acad Sci U S A. 2017;114(24):6292\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"51","key":"413_CR69","doi-asserted-by":"crossref","first-page":"39294","DOI":"10.1074\/jbc.M608085200","volume":"281","author":"V Gupta","year":"2006","unstructured":"Gupta V, et al. Lipid-induced extension of apolipoprotein E helix 4 correlates with low density lipoprotein receptor binding ability. J Biol Chem. 2006;281(51):39294\u20139.","journal-title":"J Biol Chem"},{"key":"413_CR70","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.genom.1.1.507","volume":"1","author":"RW Mahley","year":"2000","unstructured":"Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507\u201337.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"18","key":"413_CR71","doi-asserted-by":"crossref","first-page":"10771","DOI":"10.1016\/S0021-9258(18)87014-4","volume":"265","author":"RC Kowal","year":"1990","unstructured":"Kowal RC, et al. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265(18):10771\u20139.","journal-title":"J Biol Chem"},{"issue":"9","key":"413_CR72","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/nm1635","volume":"13","author":"A Sagare","year":"2007","unstructured":"Sagare A, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med. 2007;13(9):1029\u201331.","journal-title":"Nat Med"},{"issue":"2","key":"413_CR73","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1021\/bi051765s","volume":"45","author":"MJ LaDu","year":"2006","unstructured":"LaDu MJ, et al. Self-assembly of HEK cell-secreted ApoE particles resembles ApoE enrichment of lipoproteins as a ligand for the LDL receptor-related protein. Biochemistry. 2006;45(2):381\u201390.","journal-title":"Biochemistry"},{"issue":"1","key":"413_CR74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13024-018-0286-0","volume":"13","author":"Q Ma","year":"2018","unstructured":"Ma Q, et al. Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-\u03b242 by LRP1-dependent apolipoprotein E isoform-specific mechanism. Mol Neurodegener. 2018;13(1):57.","journal-title":"Mol Neurodegener"},{"issue":"1-2","key":"413_CR75","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0006-8993(01)03367-4","volume":"928","author":"BP Nathan","year":"2002","unstructured":"Nathan BP, et al. Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein. Brain Res. 2002;928(1-2):96\u2013105.","journal-title":"Brain Res"},{"issue":"2","key":"413_CR76","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1471-4159.1997.68020760.x","volume":"68","author":"PS Puttfarcken","year":"1997","unstructured":"Puttfarcken PS, et al. Effect of apolipoprotein E on neurite outgrowth and beta-amyloid-induced toxicity in developing rat primary hippocampal cultures. J Neurochem. 1997;68(2):760\u20139.","journal-title":"J Neurochem"},{"issue":"6","key":"413_CR77","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1046\/j.1471-4159.1999.0732613.x","volume":"73","author":"B Teter","year":"1999","unstructured":"Teter B, et al. Human apolipoprotein E isoform-specific differences in neuronal sprouting in organotypic hippocampal culture. J Neurochem. 1999;73(6):2613\u20136.","journal-title":"J Neurochem"},{"issue":"21","key":"413_CR78","doi-asserted-by":"crossref","first-page":"9480","DOI":"10.1073\/pnas.92.21.9480","volume":"92","author":"DM Holtzman","year":"1995","unstructured":"Holtzman DM, et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc Natl Acad Sci U S A. 1995;92(21):9480\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"47","key":"413_CR79","doi-asserted-by":"crossref","first-page":"30121","DOI":"10.1074\/jbc.271.47.30121","volume":"271","author":"AM Fagan","year":"1996","unstructured":"Fagan AM, et al. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem. 1996;271(47):30121\u20135.","journal-title":"J Biol Chem"},{"issue":"5160","key":"413_CR80","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.8171342","volume":"264","author":"BP Nathan","year":"1994","unstructured":"Nathan BP, et al. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 1994;264(5160):850\u20132.","journal-title":"Science"},{"issue":"12","key":"413_CR81","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1172\/JCI36663","volume":"118","author":"R Deane","year":"2008","unstructured":"Deane R, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118(12):4002\u201313.","journal-title":"J Clin Invest"},{"issue":"2","key":"413_CR82","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0896-6273(00)80860-0","volume":"24","author":"G D'Arcangelo","year":"1999","unstructured":"D'Arcangelo G, et al. Reelin is a ligand for lipoprotein receptors. Neuron. 1999;24(2):471\u20139.","journal-title":"Neuron"},{"issue":"2","key":"413_CR83","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0896-6273(00)80861-2","volume":"24","author":"T Hiesberger","year":"1999","unstructured":"Hiesberger T, et al. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron. 1999;24(2):481\u20139.","journal-title":"Neuron"},{"issue":"1","key":"413_CR84","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0896-6273(03)00819-5","volume":"41","author":"S Niu","year":"2004","unstructured":"Niu S, et al. Reelin promotes hippocampal dendrite development through the VLDLR\/ApoER2-Dab1 pathway. Neuron. 2004;41(1):71\u201384.","journal-title":"Neuron"},{"key":"413_CR85","doi-asserted-by":"crossref","unstructured":"Xian X, et al. Reversal of ApoE4-induced recycling block as a novel prevention approach for Alzheimer's disease. Elife. 2018;7:e40048.","DOI":"10.7554\/eLife.40048"},{"issue":"11","key":"413_CR86","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","volume":"25","author":"JF Arboleda-Velasquez","year":"2019","unstructured":"Arboleda-Velasquez JF, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25(11):1680\u20133.","journal-title":"Nat Med"},{"issue":"12","key":"413_CR87","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41577-018-0051-1","volume":"18","author":"Y Shi","year":"2018","unstructured":"Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol. 2018;18(12):759\u201372.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"413_CR88","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1084\/jem.20171265","volume":"215","author":"JD Ulrich","year":"2018","unstructured":"Ulrich JD, et al. ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med. 2018;215(4):1047\u201358.","journal-title":"J Exp Med"},{"issue":"7","key":"413_CR89","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell. 2017;169(7):1276\u20131290.e17.","journal-title":"Cell"},{"issue":"3","key":"413_CR90","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann S, et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity. 2017;47(3):566\u2013581.e9.","journal-title":"Immunity"},{"issue":"7","key":"413_CR91","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1161\/ATVBAHA.116.307023","volume":"36","author":"RW Mahley","year":"2016","unstructured":"Mahley RW. Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism. Arterioscler Thromb Vasc Biol. 2016;36(7):1305\u201315.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"413_CR92","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.atherosclerosis.2016.10.037","volume":"255","author":"KL Rasmussen","year":"2016","unstructured":"Rasmussen KL. Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review. Atherosclerosis. 2016;255:145\u201355.","journal-title":"Atherosclerosis"},{"issue":"7","key":"413_CR93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219668","volume":"14","author":"FJ Wolters","year":"2019","unstructured":"Wolters FJ, et al. The impact of APOE genotype on survival: Results of 38,537 participants from six population-based cohorts (E2-CHARGE). PLoS One. 2019;14(7):e0219668.","journal-title":"PLoS One"},{"issue":"11","key":"413_CR94","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/S0022-2275(20)32417-2","volume":"40","author":"RW Mahley","year":"1999","unstructured":"Mahley RW, Huang Y, Rall SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res. 1999;40(11):1933\u201349.","journal-title":"J Lipid Res"},{"issue":"2","key":"413_CR95","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/hq0202.102919","volume":"22","author":"F de Beer","year":"2002","unstructured":"de Beer F, et al. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia. Arterioscler Thromb Vasc Biol. 2002;22(2):294\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"28","key":"413_CR96","doi-asserted-by":"crossref","first-page":"17483","DOI":"10.1074\/jbc.273.28.17483","volume":"273","author":"Y Huang","year":"1998","unstructured":"Huang Y, et al. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J Biol Chem. 1998;273(28):17483\u201390.","journal-title":"J Biol Chem"},{"issue":"8023","key":"413_CR97","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0140-6736(77)92717-9","volume":"1","author":"A Chait","year":"1977","unstructured":"Chait A, et al. Type-III Hyperlipoproteinaemia (\"remnant removal disease\"). Insight into the pathogenetic mechanism. Lancet. 1977;1(8023):1176\u20138.","journal-title":"Lancet"},{"issue":"9","key":"413_CR98","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0026-0495(78)90151-8","volume":"27","author":"A Chait","year":"1978","unstructured":"Chait A, et al. Impaired very low density lipoprotein and triglyceride removal in broad beta disease: comparison with endogenous hypertriglyceridemia. Metabolism. 1978;27(9):1055\u201366.","journal-title":"Metabolism"},{"key":"413_CR99","doi-asserted-by":"crossref","first-page":"104811","DOI":"10.1016\/j.nbd.2020.104811","volume":"139","author":"CT Lewandowski","year":"2020","unstructured":"Lewandowski CT, Maldonado Weng J, LaDu MJ. Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How. Neurobiol Dis. 2020;139:104811.","journal-title":"Neurobiol Dis"},{"issue":"7","key":"413_CR100","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1074\/jbc.M508915200","volume":"281","author":"B Karten","year":"2006","unstructured":"Karten B, et al. Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia. J Biol Chem. 2006;281(7):4049\u201357.","journal-title":"J Biol Chem"},{"issue":"5","key":"413_CR101","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1074\/jbc.M607831200","volume":"282","author":"WS Kim","year":"2007","unstructured":"Kim WS, et al. Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation. J Biol Chem. 2007;282(5):2851\u201361.","journal-title":"J Biol Chem"},{"issue":"39","key":"413_CR102","doi-asserted-by":"crossref","first-page":"40987","DOI":"10.1074\/jbc.M407963200","volume":"279","author":"SE Wahrle","year":"2004","unstructured":"Wahrle SE, et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem. 2004;279(39):40987\u201393.","journal-title":"J Biol Chem"},{"issue":"5","key":"413_CR103","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1194\/jlr.M300418-JLR200","volume":"45","author":"L Krimbou","year":"2004","unstructured":"Krimbou L, et al. Molecular interactions between apoE and ABCA1: impact on apoE lipidation. J Lipid Res. 2004;45(5):839\u201348.","journal-title":"J Lipid Res"},{"issue":"9","key":"413_CR104","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1523\/JNEUROSCI.18-09-03261.1998","volume":"18","author":"Y Sun","year":"1998","unstructured":"Sun Y, et al. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci. 1998;18(9):3261\u201372.","journal-title":"J Neurosci"},{"issue":"42","key":"413_CR105","doi-asserted-by":"crossref","first-page":"30001","DOI":"10.1074\/jbc.274.42.30001","volume":"274","author":"AM Fagan","year":"1999","unstructured":"Fagan AM, et al. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (\u2212\/\u2212), and human apoE transgenic mice. J Biol Chem. 1999;274(42):30001\u20137.","journal-title":"J Biol Chem"},{"issue":"5","key":"413_CR106","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1046\/j.1471-4159.1998.70052070.x","volume":"70","author":"MJ LaDu","year":"1998","unstructured":"LaDu MJ, et al. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem. 1998;70(5):2070\u201381.","journal-title":"J Neurochem"},{"issue":"11","key":"413_CR107","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1523\/JNEUROSCI.4741-08.2009","volume":"29","author":"JM Karasinska","year":"2009","unstructured":"Karasinska JM, et al. Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. J Neurosci. 2009;29(11):3579\u201389.","journal-title":"J Neurosci"},{"issue":"1","key":"413_CR108","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/JAD-2010-1348","volume":"20","author":"MJ Sharman","year":"2010","unstructured":"Sharman MJ, et al. Profiling brain and plasma lipids in human APOE epsilon2, epsilon3, and epsilon4 knock-in mice using electrospray ionization mass spectrometry. J Alzheimers Dis. 2010;20(1):105\u201311.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"413_CR109","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13195-019-0558-0","volume":"11","author":"I Lefterov","year":"2019","unstructured":"Lefterov I, et al. APOE2 orchestrated differences in transcriptomic and lipidomic profiles of postmortem AD brain. Alzheimers Res Ther. 2019;11(1):113.","journal-title":"Alzheimers Res Ther"},{"issue":"5545","key":"413_CR110","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1126\/science.294.5545.1354","volume":"294","author":"DH Mauch","year":"2001","unstructured":"Mauch DH, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294(5545):1354\u20137.","journal-title":"Science"},{"issue":"48","key":"413_CR111","doi-asserted-by":"crossref","first-page":"15317","DOI":"10.1523\/JNEUROSCI.4026-09.2009","volume":"29","author":"SB Dumanis","year":"2009","unstructured":"Dumanis SB, et al. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci. 2009;29(48):15317\u201322.","journal-title":"J Neurosci"},{"key":"413_CR112","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.pharmthera.2018.11.006","volume":"195","author":"Y Chen","year":"2019","unstructured":"Chen Y, Fu AKY, Ip NY. Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies. Pharmacol Ther. 2019;195:186\u201398.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"413_CR113","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13024-019-0307-7","volume":"14","author":"S Chakroborty","year":"2019","unstructured":"Chakroborty S, et al. Reduced presynaptic vesicle stores mediate cellular and network plasticity defects in an early-stage mouse model of Alzheimer's disease. Mol Neurodegener. 2019;14(1):7.","journal-title":"Mol Neurodegener"},{"issue":"36","key":"413_CR114","doi-asserted-by":"crossref","first-page":"10186","DOI":"10.1073\/pnas.1609896113","volume":"113","author":"WS Chung","year":"2016","unstructured":"Chung WS, et al. Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes. Proc Natl Acad Sci U S A. 2016;113(36):10186\u201391.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"413_CR115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-1326-4-21","volume":"4","author":"KM Korwek","year":"2009","unstructured":"Korwek KM, et al. ApoE isoform-dependent changes in hippocampal synaptic function. Mol Neurodegener. 2009;4:21.","journal-title":"Mol Neurodegener"},{"issue":"17","key":"413_CR116","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1097\/00001756-200412030-00020","volume":"15","author":"BL Trommer","year":"2004","unstructured":"Trommer BL, et al. ApoE isoform affects LTP in human targeted replacement mice. Neuroreport. 2004;15(17):2655\u20138.","journal-title":"Neuroreport"},{"key":"413_CR117","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.08.009","volume":"94","author":"GH Weissberger","year":"2018","unstructured":"Weissberger GH, et al. Meta-analysis of cognitive ability differences by apolipoprotein e genotype in young humans. Neurosci Biobehav Rev. 2018;94:49\u201358.","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"413_CR118","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/gerona\/glt103","volume":"69","author":"D Bunce","year":"2014","unstructured":"Bunce D, et al. APOE genotype and cognitive change in young, middle-aged, and older adults living in the community. J Gerontol A Biol Sci Med Sci. 2014;69(4):379\u201386.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"413_CR119","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/jgs.15727","volume":"67","author":"KB Rajan","year":"2019","unstructured":"Rajan KB, et al. Apolipoprotein E Genotypes, Age, Race, and Cognitive Decline in a Population Sample. J Am Geriatr Soc. 2019;67(4):734\u201340.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"413_CR120","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1037\/neu0000501","volume":"33","author":"ET Reas","year":"2019","unstructured":"Reas ET, et al. Effects of APOE on cognitive aging in community-dwelling older adults. Neuropsychology. 2019;33(3):406\u201316.","journal-title":"Neuropsychology"},{"issue":"6","key":"413_CR121","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358\u201372.","journal-title":"Nat Rev Neurosci"},{"issue":"6343","key":"413_CR122","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1126\/science.aan7893","volume":"356","author":"GC Brown","year":"2017","unstructured":"Brown GC, St George-Hyslop PH. Deciphering microglial diversity in Alzheimer's disease. Science. 2017;356(6343):1123\u20134.","journal-title":"Science"},{"issue":"6","key":"413_CR123","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","volume":"160","author":"Y Wang","year":"2015","unstructured":"Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015;160(6):1061\u201371.","journal-title":"Cell"},{"issue":"1","key":"413_CR124","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13024-019-0351-3","volume":"14","author":"RS Pandey","year":"2019","unstructured":"Pandey RS, et al. Genetic perturbations of disease risk genes in mice capture transcriptomic signatures of late-onset Alzheimer's disease. Mol Neurodegener. 2019;14(1):50.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"413_CR125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","volume":"13","author":"M Gratuze","year":"2018","unstructured":"Gratuze M, Leyns CEG, Holtzman DM. New insights into the role of TREM2 in Alzheimer's disease. Mol Neurodegener. 2018;13(1):66.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"413_CR126","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41591-019-0695-9","volume":"26","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nature medicine. 2020;26(1):131\u201342.","journal-title":"Nature medicine"},{"key":"413_CR127","doi-asserted-by":"crossref","unstructured":"Mathys H, et al. Single-cell transcriptomic analysis of Alzheimer\u2019s disease. Nature. 2019;570(7761):332\u20137.","DOI":"10.1038\/s41586-019-1195-2"},{"issue":"4","key":"413_CR128","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.celrep.2019.03.099","volume":"27","author":"C Sala Frigerio","year":"2019","unstructured":"Sala Frigerio C, et al. The Major Risk Factors for Alzheimer's Disease: Age, Sex, and Genes Modulate the Microglia Response to A\u03b2 Plaques. Cell Rep. 2019;27(4):1293\u20131306.e6.","journal-title":"Cell Rep"},{"issue":"2","key":"413_CR129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41593-018-0296-9","volume":"22","author":"S Parhizkar","year":"2019","unstructured":"Parhizkar S, et al. Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nat Neurosci. 2019;22(2):191\u2013204.","journal-title":"Nat Neurosci"},{"issue":"1","key":"413_CR130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13024-020-00394-4","volume":"15","author":"NF Fitz","year":"2020","unstructured":"Fitz NF, et al. Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice. Mol Neurodegener. 2020;15(1):41.","journal-title":"Mol Neurodegener"},{"issue":"7673","key":"413_CR131","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523\u20137.","journal-title":"Nature"},{"issue":"1","key":"413_CR132","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jaci.2014.01.032","volume":"134","author":"SC Gale","year":"2014","unstructured":"Gale SC, et al. APO\u03b54 is associated with enhanced in vivo innate immune responses in human subjects. J Allergy Clin Immunol. 2014;134(1):127\u201334.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"413_CR133","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.neurobiolaging.2007.11.014","volume":"30","author":"MP Vitek","year":"2009","unstructured":"Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. Neurobiol Aging. 2009;30(9):1350\u201360.","journal-title":"Neurobiol Aging"},{"issue":"6","key":"413_CR134","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1096\/fj.05-5423fje","volume":"20","author":"I Maezawa","year":"2006","unstructured":"Maezawa I, et al. Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. Faseb j. 2006;20(6):797\u20139.","journal-title":"Faseb j"},{"issue":"4","key":"413_CR135","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/glia.22289","volume":"60","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, et al. APOE genotype alters glial activation and loss of synaptic markers in mice. Glia. 2012;60(4):559\u201369.","journal-title":"Glia"},{"issue":"3","key":"413_CR136","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133\u201350.","journal-title":"Nat Rev Neurol"},{"issue":"7399","key":"413_CR137","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature11087","volume":"485","author":"RD Bell","year":"2012","unstructured":"Bell RD, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485(7399):512\u20136.","journal-title":"Nature"},{"issue":"1","key":"413_CR138","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13024-018-0249-5","volume":"13","author":"BS Main","year":"2018","unstructured":"Main BS, et al. Apolipoprotein E4 impairs spontaneous blood brain barrier repair following traumatic brain injury. Mol Neurodegener. 2018;13(1):17.","journal-title":"Mol Neurodegener"},{"issue":"7806","key":"413_CR139","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","volume":"581","author":"A Montagne","year":"2020","unstructured":"Montagne A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71\u20136.","journal-title":"Nature"},{"issue":"1","key":"413_CR140","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/ATVBAHA.119.313169","volume":"40","author":"Y Yamazaki","year":"2020","unstructured":"Yamazaki Y, et al. ApoE (Apolipoprotein E) in Brain Pericytes Regulates Endothelial Function in an Isoform-Dependent Manner by Modulating Basement Membrane Components. Arterioscler Thromb Vasc Biol. 2020;40(1):128\u201344.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Pt 11","key":"413_CR141","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/brain\/awl256","volume":"129","author":"V Singh","year":"2006","unstructured":"Singh V, et al. Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease. Brain. 2006;129(Pt 11):2885\u201393.","journal-title":"Brain"},{"issue":"7","key":"413_CR142","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/cercor\/bhh200","volume":"15","author":"JP Lerch","year":"2005","unstructured":"Lerch JP, et al. Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex. 2005;15(7):995\u20131001.","journal-title":"Cereb Cortex"},{"issue":"4","key":"413_CR143","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3233\/JAD-2010-100114","volume":"21","author":"V Julkunen","year":"2010","unstructured":"Julkunen V, et al. Differences in cortical thickness in healthy controls, subjects with mild cognitive impairment, and Alzheimer's disease patients: a longitudinal study. J Alzheimers Dis. 2010;21(4):1141\u201351.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"413_CR144","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jalz.2016.08.010","volume":"13","author":"J Pegueroles","year":"2017","unstructured":"Pegueroles J, et al. Longitudinal brain structural changes in preclinical Alzheimer's disease. Alzheimers Dement. 2017;13(5):499\u2013509.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"413_CR145","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.42.1.183","volume":"42","author":"CR Jack Jr","year":"1992","unstructured":"Jack CR Jr, et al. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology. 1992;42(1):183\u20138.","journal-title":"Neurology"},{"issue":"9","key":"413_CR146","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archneur.1993.00540090052010","volume":"50","author":"RJ Killiany","year":"1993","unstructured":"Killiany RJ, et al. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol. 1993;50(9):949\u201354.","journal-title":"Arch Neurol"},{"issue":"6","key":"413_CR147","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(07)70106-0","volume":"6","author":"P Shaw","year":"2007","unstructured":"Shaw P, et al. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol. 2007;6(6):494\u2013500.","journal-title":"Lancet Neurol"},{"issue":"6","key":"413_CR148","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1212\/WNL.0000000000002939","volume":"87","author":"L Chang","year":"2016","unstructured":"Chang L, et al. Gray matter maturation and cognition in children with different APOE epsilon genotypes. Neurology. 2016;87(6):585\u201394.","journal-title":"Neurology"},{"issue":"1","key":"413_CR149","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/JAD-131841","volume":"40","author":"W Khan","year":"2014","unstructured":"Khan W, et al. No differences in hippocampal volume between carriers and non-carriers of the ApoE \u03b54 and \u03b52 alleles in young healthy adolescents. J Alzheimers Dis. 2014;40(1):37\u201343.","journal-title":"J Alzheimers Dis"},{"issue":"Suppl 3","key":"413_CR150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-0002","volume":"26","author":"C Fennema-Notestine","year":"2011","unstructured":"Fennema-Notestine C, et al. Presence of ApoE \u03b54 allele associated with thinner frontal cortex in middle age. J Alzheimers Dis. 2011;26(Suppl 3):49\u201360.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"413_CR151","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neulet.2010.05.092","volume":"479","author":"M Fan","year":"2010","unstructured":"Fan M, et al. Cortical thickness is associated with different apolipoprotein E genotypes in healthy elderly adults. Neurosci Lett. 2010;479(3):332\u20136.","journal-title":"Neurosci Lett"},{"issue":"2","key":"413_CR152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054483","volume":"8","author":"CA Hostage","year":"2013","unstructured":"Hostage CA, et al. Dissecting the gene dose-effects of the APOE \u03b54 and \u03b52 alleles on hippocampal volumes in aging and Alzheimer's disease. PLoS One. 2013;8(2):e54483.","journal-title":"PLoS One"},{"issue":"5","key":"413_CR153","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1212\/WNL.59.5.746","volume":"59","author":"T den Heijer","year":"2002","unstructured":"den Heijer T, et al. Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology. 2002;59(5):746\u20138.","journal-title":"Neurology"},{"issue":"3","key":"413_CR154","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000320136","volume":"30","author":"Y Liu","year":"2010","unstructured":"Liu Y, et al. APOE \u03b52 allele is associated with larger regional cortical thicknesses and volumes. Dement Geriatr Cogn Disord. 2010;30(3):229\u201337.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"413_CR155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nlm.2017.10.008","volume":"146","author":"LI Sinclair","year":"2017","unstructured":"Sinclair LI, Pleydell-Pearce CW, Day INM. Possible positive effect of the APOE epsilon2 allele on cognition in early to mid-adult life. Neurobiol Learn Mem. 2017;146:37\u201346.","journal-title":"Neurobiol Learn Mem"},{"issue":"2","key":"413_CR156","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.biopsych.2010.10.033","volume":"70","author":"AE Taylor","year":"2011","unstructured":"Taylor AE, et al. IQ, educational attainment, memory and plasma lipids: associations with apolipoprotein E genotype in 5995 children. Biol Psychiatry. 2011;70(2):152\u20138.","journal-title":"Biol Psychiatry"},{"issue":"11","key":"413_CR157","volume":"10","author":"XF Chen","year":"2015","unstructured":"Chen XF, et al. Demographic and Lifestyle Characteristics, but Not Apolipoprotein E Genotype, Are Associated with Intelligence among Young Chinese College Students. PLoS One. 2015;10(11):e0143157.","journal-title":"PLoS One"},{"issue":"3","key":"413_CR158","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0304-3940(95)11575-H","volume":"191","author":"EL Helkala","year":"1995","unstructured":"Helkala EL, et al. The association of apolipoprotein E polymorphism with memory: a population based study. Neurosci Lett. 1995;191(3):141\u20134.","journal-title":"Neurosci Lett"},{"issue":"3","key":"413_CR159","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0304-3940(00)01288-X","volume":"289","author":"J Chey","year":"2000","unstructured":"Chey J, Kim JW, Cho HY. Effects of apolipoprotein E phenotypes on the neuropsychological functions of community-dwelling elderly individuals without dementia. Neurosci Lett. 2000;289(3):230\u20134.","journal-title":"Neurosci Lett"},{"issue":"4","key":"413_CR160","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.neurobiolaging.2004.05.003","volume":"26","author":"JH Kang","year":"2005","unstructured":"Kang JH, et al. Apolipoprotein E, cardiovascular disease and cognitive function in aging women. Neurobiol Aging. 2005;26(4):475\u201384.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"413_CR161","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1212\/01.WNL.0000149643.91367.8A","volume":"64","author":"CK Blair","year":"2005","unstructured":"Blair CK, et al. APOE genotype and cognitive decline in a middle-aged cohort. Neurology. 2005;64(2):268\u201376.","journal-title":"Neurology"},{"issue":"3","key":"413_CR162","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0304-3940(96)12348-X","volume":"204","author":"EL Helkala","year":"1996","unstructured":"Helkala EL, et al. Memory functions in human subjects with different apolipoprotein E phenotypes during a 3-year population-based follow-up study. Neurosci Lett. 1996;204(3):177\u201380.","journal-title":"Neurosci Lett"},{"issue":"1","key":"413_CR163","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ana.410400111","volume":"40","author":"BT Hyman","year":"1996","unstructured":"Hyman BT, et al. Apolipoprotein E and cognitive change in an elderly population. Ann Neurol. 1996;40(1):55\u201366.","journal-title":"Ann Neurol"},{"issue":"1","key":"413_CR164","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/gepi.1370100104","volume":"10","author":"JA Cauley","year":"1993","unstructured":"Cauley JA, et al. Apo E allele frequencies in younger (age 42-50) vs older (age 65-90) women. Genet Epidemiol. 1993;10(1):27\u201334.","journal-title":"Genet Epidemiol"},{"issue":"1","key":"413_CR165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ng0194-29","volume":"6","author":"F Schachter","year":"1994","unstructured":"Schachter F, et al. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet. 1994;6(1):29\u201332.","journal-title":"Nat Genet"},{"issue":"4","key":"413_CR166","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3143\/geriatrics.34.267","volume":"34","author":"N Hirose","year":"1997","unstructured":"Hirose N, et al. Tokyo Centenarian Study. 4. Apolipoprotein E phenotype in Japanese centenarians living in the Tokyo Metropolitan area. Nihon Ronen Igakkai Zasshi. 1997;34(4):267\u201372.","journal-title":"Nihon Ronen Igakkai Zasshi"},{"issue":"2","key":"413_CR167","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0047-6374(98)00067-0","volume":"104","author":"Z Jian-Gang","year":"1998","unstructured":"Jian-Gang Z, et al. Apolipoprotein E and longevity among Han Chinese population. Mech Ageing Dev. 1998;104(2):159\u201367.","journal-title":"Mech Ageing Dev"},{"issue":"2","key":"413_CR168","doi-asserted-by":"crossref","first-page":"M75","DOI":"10.1093\/gerona\/56.2.M75","volume":"56","author":"GB Frisoni","year":"2001","unstructured":"Frisoni GB, et al. Longevity and the epsilon2 allele of apolipoprotein E: the Finnish Centenarians Study. J Gerontol A Biol Sci Med Sci. 2001;56(2):M75\u20138.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"15","key":"413_CR169","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJM200104123441501","volume":"344","author":"C Wolfson","year":"2001","unstructured":"Wolfson C, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344(15):1111\u20136.","journal-title":"N Engl J Med"},{"issue":"1","key":"413_CR170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004141","volume":"10","author":"AM Kulminski","year":"2014","unstructured":"Kulminski AM, et al. Age, gender, and cancer but not neurodegenerative and cardiovascular diseases strongly modulate systemic effect of the Apolipoprotein E4 allele on lifespan. PLoS Genet. 2014;10(1):e1004141.","journal-title":"PLoS Genet"},{"issue":"8920","key":"413_CR171","first-page":"473","volume":"344","author":"AD Smith","year":"1994","unstructured":"Smith AD, et al. Protective effect of apo epsilon 2 in Alzheimer's disease. Oxford Project to Investigate Memory and Ageing (OPTIMA). Lancet. 1994;344(8920):473\u20134.","journal-title":"Lancet"},{"issue":"1-2","key":"413_CR172","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0304-3940(94)91074-X","volume":"175","author":"HL West","year":"1994","unstructured":"West HL, William Rebeck G, Hyman BT. Frequency of the apolipoprotein E \u03b52 allele is diminished in sporadic Alzheimer disease. Neurosci Lett. 1994;175(1-2):46\u20138.","journal-title":"Neurosci Lett"},{"issue":"12","key":"413_CR173","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1212\/01.wnl.0000188871.74093.12","volume":"65","author":"CA Martins","year":"2005","unstructured":"Martins CA, et al. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology. 2005;65(12):1888\u201393.","journal-title":"Neurology"},{"issue":"3","key":"413_CR174","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41582-018-0132-6","volume":"15","author":"IT Lott","year":"2019","unstructured":"Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat Rev Neurol. 2019;15(3):135\u201347.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"413_CR175","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0006-3223(97)00481-2","volume":"43","author":"J Tyrrell","year":"1998","unstructured":"Tyrrell J, et al. A protective effect of apolipoprotein E e2 allele on dementia in Down's syndrome. Biol Psychiatry. 1998;43(6):397\u2013400.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"413_CR176","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1212\/WNL.53.2.331","volume":"53","author":"F Lai","year":"1999","unstructured":"Lai F, et al. APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. Neurology. 1999;53(2):331\u20136.","journal-title":"Neurology"},{"issue":"1","key":"413_CR177","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0304-3940(96)13244-4","volume":"220","author":"JC Lambert","year":"1996","unstructured":"Lambert JC, et al. Analysis of the APOE alleles impact in Down's syndrome. Neurosci Lett. 1996;220(1):57\u201360.","journal-title":"Neurosci Lett"},{"issue":"10","key":"413_CR178","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaneurol.2017.2188","volume":"74","author":"SC Neu","year":"2017","unstructured":"Neu SC, et al. Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol. 2017;74(10):1178\u201389.","journal-title":"JAMA Neurol"},{"issue":"8","key":"413_CR179","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003289","volume":"17","author":"H Saddiki","year":"2020","unstructured":"Saddiki H, et al. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. PLoS Med. 2020;17(8):e1003289.","journal-title":"PLoS Med"},{"issue":"3-4","key":"413_CR180","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/17588928.2013.831820","volume":"4","author":"C Pettigrew","year":"2013","unstructured":"Pettigrew C, et al. Relationship of cognitive reserve and APOE status to the emergence of clinical symptoms in preclinical Alzheimer's disease. Cogn Neurosci. 2013;4(3-4):136\u201342.","journal-title":"Cogn Neurosci"},{"issue":"7","key":"413_CR181","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3115","volume":"9","author":"H Hampel","year":"2010","unstructured":"Hampel H, et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9(7):560\u201374.","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"413_CR182","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","volume":"85","author":"S Palmqvist","year":"2015","unstructured":"Palmqvist S, et al. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology. 2015;85(14):1240\u20139.","journal-title":"Neurology"},{"issue":"8","key":"413_CR183","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221365","volume":"14","author":"EG M\u00fcller","year":"2019","unstructured":"M\u00fcller EG, et al. Amyloid-\u03b2 PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer\u2019s disease diagnosis in a memory clinic. PLoS One. 2019;14(8):e0221365.","journal-title":"PLoS One"},{"issue":"4","key":"413_CR184","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk D, et al. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60(4):652\u20136.","journal-title":"Neurology"},{"issue":"1","key":"413_CR185","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.21843","volume":"67","author":"JC Morris","year":"2010","unstructured":"Morris JC, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122\u201331.","journal-title":"Ann Neurol"},{"issue":"11","key":"413_CR186","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188501","volume":"12","author":"TJ Hohman","year":"2017","unstructured":"Hohman TJ, et al. APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer's Disease. PLoS One. 2017;12(11):e0188501.","journal-title":"PLoS One"},{"issue":"5","key":"413_CR187","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jamaneurol.2018.4693","volume":"76","author":"RF Buckley","year":"2019","unstructured":"Buckley RF, et al. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurol. 2019;76(5):542\u201351.","journal-title":"JAMA Neurol"},{"issue":"6","key":"413_CR188","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1212\/WNL.0000000000003585","volume":"88","author":"MJ Grothe","year":"2017","unstructured":"Grothe MJ, et al. Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load. Neurology. 2017;88(6):569\u201376.","journal-title":"Neurology"},{"issue":"4","key":"413_CR189","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.jalz.2010.05.394","volume":"6","author":"DJ Berlau","year":"2010","unstructured":"Berlau DJ, et al. Neocortical beta-amyloid area, but not CERAD plaque stage, is associated with dementia status and Apolipoprotein E (APOE) genotype in the oldest old. Alzheimer's & Dementia. 2010;6(4):S125\u20136.","journal-title":"Alzheimer's & Dementia"},{"issue":"9","key":"413_CR190","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1194\/jlr.R076315","volume":"58","author":"LM Tai","year":"2017","unstructured":"Tai LM, et al. EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease. J Lipid Res. 2017;58(9):1733\u201355.","journal-title":"J Lipid Res"},{"issue":"50","key":"413_CR191","doi-asserted-by":"crossref","first-page":"41774","DOI":"10.1074\/jbc.M112.407957","volume":"287","author":"KL Youmans","year":"2012","unstructured":"Youmans KL, et al. APOE4-specific changes in A\u03b2 accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem. 2012;287(50):41774\u201386.","journal-title":"J Biol Chem"},{"issue":"21","key":"413_CR192","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1523\/JNEUROSCI.0887-09.2009","volume":"29","author":"KR Bales","year":"2009","unstructured":"Bales KR, et al. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci. 2009;29(21):6771\u20139.","journal-title":"J Neurosci"},{"issue":"4","key":"413_CR193","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1073\/pnas.0409072102","volume":"102","author":"JC Dodart","year":"2005","unstructured":"Dodart JC, et al. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2005;102(4):1211\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"212","key":"413_CR194","doi-asserted-by":"crossref","first-page":"212ra161","DOI":"10.1126\/scitranslmed.3007000","volume":"5","author":"E Hudry","year":"2013","unstructured":"Hudry E, et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med. 2013;5(212):212ra161.","journal-title":"Sci Transl Med"},{"issue":"6","key":"413_CR195","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595\u2013608.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"413_CR196","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1006\/nbdi.1995.0019","volume":"2","author":"AL Biere","year":"1995","unstructured":"Biere AL, et al. Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing. Neurobiol Dis. 1995;2(3):177\u201387.","journal-title":"Neurobiol Dis"},{"issue":"5","key":"413_CR197","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1471-4159.2004.02581.x","volume":"90","author":"MC Irizarry","year":"2004","unstructured":"Irizarry MC, et al. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. J Neurochem. 2004;90(5):1132\u201343.","journal-title":"J Neurochem"},{"issue":"89","key":"413_CR198","doi-asserted-by":"crossref","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"JM Castellano","year":"2011","unstructured":"Castellano JM, et al. Human apoE isoforms differentially regulate brain amyloid-\u03b2 peptide clearance. Sci Transl Med. 2011;3(89):89ra57.","journal-title":"Sci Transl Med"},{"issue":"3","key":"413_CR199","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cell.2016.12.044","volume":"168","author":"YA Huang","year":"2017","unstructured":"Huang YA, et al. ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Abeta Secretion. Cell. 2017;168(3):427\u201341. e21.","journal-title":"Cell"},{"issue":"5","key":"413_CR200","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.neuron.2020.02.034","volume":"106","author":"N Zhao","year":"2020","unstructured":"Zhao N, et al. Alzheimer's Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways. Neuron. 2020;106(5):727\u2013742.e6.","journal-title":"Neuron"},{"issue":"8","key":"413_CR201","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway JM, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015;11(8):457\u201370.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"413_CR202","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1523\/JNEUROSCI.5302-08.2009","volume":"29","author":"L Zhao","year":"2009","unstructured":"Zhao L, et al. Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism. J Neurosci. 2009;29(11):3603\u201312.","journal-title":"J Neurosci"},{"issue":"5","key":"413_CR203","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","volume":"58","author":"Q Jiang","year":"2008","unstructured":"Jiang Q, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58(5):681\u201393.","journal-title":"Neuron"},{"issue":"2","key":"413_CR204","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","volume":"15","author":"F Panza","year":"2019","unstructured":"Panza F, et al. A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15(2):73\u201388.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"413_CR205","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nn.3028","volume":"15","author":"I Benilova","year":"2012","unstructured":"Benilova I, Karran E, De Strooper B. The toxic A\u03b2 oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci. 2012;15(3):349\u201357.","journal-title":"Nat Neurosci"},{"issue":"43","key":"413_CR206","doi-asserted-by":"crossref","first-page":"15181","DOI":"10.1523\/JNEUROSCI.1542-12.2012","volume":"32","author":"T Hashimoto","year":"2012","unstructured":"Hashimoto T, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J Neurosci. 2012;32(43):15181\u201392.","journal-title":"J Neurosci"},{"issue":"2","key":"413_CR207","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1039\/C6CS00731G","volume":"46","author":"SJ Lee","year":"2017","unstructured":"Lee SJ, et al. Towards an understanding of amyloid-\u03b2 oligomers: characterization, toxicity mechanisms, and inhibitors. Chem Soc Rev. 2017;46(2):310\u201323.","journal-title":"Chem Soc Rev"},{"issue":"1","key":"413_CR208","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng0996-55","volume":"14","author":"M Miyata","year":"1996","unstructured":"Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996;14(1):55\u201361.","journal-title":"Nat Genet"},{"issue":"1","key":"413_CR209","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nbd.2004.08.011","volume":"18","author":"BL Trommer","year":"2005","unstructured":"Trommer BL, et al. ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. Neurobiol Dis. 2005;18(1):75\u201382.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"413_CR210","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0969-9961(03)00079-2","volume":"13","author":"TA Lanz","year":"2003","unstructured":"Lanz TA, Carter DB, Merchant KM. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis. 2003;13(3):246\u201353.","journal-title":"Neurobiol Dis"},{"issue":"14","key":"413_CR211","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1523\/JNEUROSCI.4213-04.2005","volume":"25","author":"MM Wilhelmus","year":"2005","unstructured":"Wilhelmus MM, et al. Apolipoprotein E genotype regulates amyloid-beta cytotoxicity. J Neurosci. 2005;25(14):3621\u20137.","journal-title":"J Neurosci"},{"issue":"5","key":"413_CR212","first-page":"821","volume":"17","author":"M Folin","year":"2006","unstructured":"Folin M, et al. Apolipoprotein-E modulates the cytotoxic effect of beta-amyloid on rat brain endothelium in an isoform-dependent specific manner. Int J Mol Med. 2006;17(5):821\u20136.","journal-title":"Int J Mol Med"},{"issue":"4","key":"413_CR213","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","volume":"81","author":"T Kanekiyo","year":"2014","unstructured":"Kanekiyo T, Xu H, Bu G. ApoE and Abeta in Alzheimer's disease: accidental encounters or partners? Neuron. 2014;81(4):740\u201354.","journal-title":"Neuron"},{"key":"413_CR214","doi-asserted-by":"crossref","first-page":"134285","DOI":"10.1016\/j.neulet.2019.134285","volume":"707","author":"D Balu","year":"2019","unstructured":"Balu D, et al. The role of APOE in transgenic mouse models of AD. Neurosci Lett. 2019;707:134285.","journal-title":"Neurosci Lett"},{"issue":"17","key":"413_CR215","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1073\/pnas.90.17.8098","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter WJ, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(17):8098\u2013102.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"413_CR216","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter WJ, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(5):1977\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"38","key":"413_CR217","doi-asserted-by":"crossref","first-page":"23403","DOI":"10.1016\/S0021-9258(17)31529-6","volume":"269","author":"MJ LaDu","year":"1994","unstructured":"LaDu MJ, et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 1994;269(38):23403\u20136.","journal-title":"J Biol Chem"},{"issue":"16","key":"413_CR218","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1074\/jbc.270.16.9039","volume":"270","author":"MJ LaDu","year":"1995","unstructured":"LaDu MJ, et al. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J Biol Chem. 1995;270(16):9039\u201342.","journal-title":"J Biol Chem"},{"issue":"2","key":"413_CR219","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1471-4159.1997.68020721.x","volume":"68","author":"DS Yang","year":"1997","unstructured":"Yang DS, et al. Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J Neurochem. 1997;68(2):721\u20135.","journal-title":"J Neurochem"},{"issue":"1","key":"413_CR220","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1046\/j.1471-4159.1999.0720230.x","volume":"72","author":"T Pillot","year":"1999","unstructured":"Pillot T, et al. Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease. J Neurochem. 1999;72(1):230\u20137.","journal-title":"J Neurochem"},{"issue":"34","key":"413_CR221","doi-asserted-by":"crossref","first-page":"10571","DOI":"10.1021\/bi9626362","volume":"36","author":"S Aleshkov","year":"1997","unstructured":"Aleshkov S, Abraham CR, Zannis VI. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Biochemistry. 1997;36(34):10571\u201380.","journal-title":"Biochemistry"},{"issue":"8","key":"413_CR222","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1074\/jbc.M112.442103","volume":"288","author":"LM Tai","year":"2013","unstructured":"Tai LM, et al. Levels of soluble apolipoprotein E\/amyloid-\u03b2 (A\u03b2) complex are reduced and oligomeric A\u03b2 increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem. 2013;288(8):5914\u201326.","journal-title":"J Biol Chem"},{"issue":"1","key":"413_CR223","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0006-8993(91)91092-F","volume":"541","author":"Y Namba","year":"1991","unstructured":"Namba Y, et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541(1):163\u20136.","journal-title":"Brain Res"},{"key":"413_CR224","first-page":"75","volume":"2","author":"JE Pankiewicz","year":"2014","unstructured":"Pankiewicz JE, et al. Blocking the apoE\/A\u03b2 interaction ameliorates A\u03b2-related pathology in APOE \u03b52 and \u03b54 targeted replacement Alzheimer model mice. Acta Neuropathol Commun. 2014;2:75.","journal-title":"Acta Neuropathol Commun"},{"issue":"19","key":"413_CR225","doi-asserted-by":"crossref","first-page":"E1807","DOI":"10.1073\/pnas.1220484110","volume":"110","author":"PB Verghese","year":"2013","unstructured":"Verghese PB, et al. ApoE influences amyloid-\u03b2 (A\u03b2) clearance despite minimal apoE\/A\u03b2 association in physiological conditions. Proc Natl Acad Sci U S A. 2013;110(19):E1807\u201316.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"413_CR226","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.neuron.2017.11.013","volume":"96","author":"CC Liu","year":"2017","unstructured":"Liu CC, et al. ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron. 2017;96(5):1024\u20131032.e3.","journal-title":"Neuron"},{"issue":"5","key":"413_CR227","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.neuron.2017.11.014","volume":"96","author":"TV Huynh","year":"2017","unstructured":"Huynh TV, et al. Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of \u03b2-amyloidosis. Neuron. 2017;96(5):1013\u20131023.e4.","journal-title":"Neuron"},{"issue":"1","key":"413_CR228","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41583-019-0240-3","volume":"21","author":"R van der Kant","year":"2020","unstructured":"van der Kant R, Goldstein LSB, Ossenkoppele R. Amyloid-beta-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci. 2020;21(1):21\u201335.","journal-title":"Nat Rev Neurosci"},{"key":"413_CR229","doi-asserted-by":"crossref","unstructured":"Busche MA, Hyman BT. Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat Neurosci. 2020;23(10):1183\u201393.","DOI":"10.1038\/s41593-020-0687-6"},{"issue":"1","key":"413_CR230","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener. 2019;14(1):32.","journal-title":"Mol Neurodegener"},{"key":"413_CR231","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neurobiolaging.2015.09.011","volume":"37","author":"JM Farfel","year":"2016","unstructured":"Farfel JM, et al. Association of APOE with tau-tangle pathology with and without beta-amyloid. Neurobiol Aging. 2016;37:19\u201325.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"413_CR232","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13024-017-0231-7","volume":"12","author":"JL Jankowsky","year":"2017","unstructured":"Jankowsky JL, Zheng H. Practical considerations for choosing a mouse model of Alzheimer's disease. Mol Neurodegener. 2017;12(1):89.","journal-title":"Mol Neurodegener"},{"issue":"10","key":"413_CR233","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41583-018-0054-8","volume":"19","author":"J G\u00f6tz","year":"2018","unstructured":"G\u00f6tz J, Bodea LG, Goedert M. Rodent models for Alzheimer disease. Nat Rev Neurosci. 2018;19(10):583\u201398.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"413_CR234","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13024-017-0162-3","volume":"12","author":"L Saint-Aubert","year":"2017","unstructured":"Saint-Aubert L, et al. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;12(1):19.","journal-title":"Mol Neurodegener"},{"issue":"8","key":"413_CR235","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","volume":"24","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24(8):1112\u201334.","journal-title":"Mol Psychiatry"},{"issue":"10","key":"413_CR236","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/jnen\/nlw067","volume":"75","author":"NM Heinsinger","year":"2016","unstructured":"Heinsinger NM, Gachechiladze MA, Rebeck GW. Apolipoprotein E Genotype Affects Size of ApoE Complexes in Cerebrospinal Fluid. J Neuropathol Exp Neurol. 2016;75(10):918\u201324.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1-2","key":"413_CR237","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.nbd.2004.11.005","volume":"19","author":"M Morikawa","year":"2005","unstructured":"Morikawa M, et al. Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta. Neurobiol Dis. 2005;19(1-2):66\u201376.","journal-title":"Neurobiol Dis"},{"issue":"Pt 2","key":"413_CR238","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1042\/bj3480359","volume":"348","author":"T Tokuda","year":"2000","unstructured":"Tokuda T, et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J. 2000;348(Pt 2):359\u201365.","journal-title":"Biochem J"},{"issue":"3","key":"413_CR239","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"J Kim","year":"2009","unstructured":"Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009;63(3):287\u2013303.","journal-title":"Neuron"},{"issue":"12","key":"413_CR240","first-page":"3900","volume":"117","author":"L Yvan-Charvet","year":"2007","unstructured":"Yvan-Charvet L, et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest. 2007;117(12):3900\u20138.","journal-title":"J Clin Invest"},{"issue":"18","key":"413_CR241","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/CIRCULATIONAHA.108.793869","volume":"118","author":"L Yvan-Charvet","year":"2008","unstructured":"Yvan-Charvet L, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation. 2008;118(18):1837\u201347.","journal-title":"Circulation"},{"issue":"3","key":"413_CR242","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1471-4159.2000.0741008.x","volume":"74","author":"M Michikawa","year":"2000","unstructured":"Michikawa M, et al. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem. 2000;74(3):1008\u201316.","journal-title":"J Neurochem"},{"issue":"2","key":"413_CR243","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/01.ATV.0000054199.78458.4B","volume":"23","author":"M Hara","year":"2003","unstructured":"Hara M, et al. Isoform-dependent cholesterol efflux from macrophages by apolipoprotein E is modulated by cell surface proteoglycans. Arterioscler Thromb Vasc Biol. 2003;23(2):269\u201374.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"52","key":"413_CR244","doi-asserted-by":"crossref","first-page":"43236","DOI":"10.1074\/jbc.M508780200","volume":"280","author":"SE Wahrle","year":"2005","unstructured":"Wahrle SE, et al. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005;280(52):43236\u201342.","journal-title":"J Biol Chem"},{"issue":"2","key":"413_CR245","first-page":"671","volume":"118","author":"SE Wahrle","year":"2008","unstructured":"Wahrle SE, et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008;118(2):671\u201382.","journal-title":"J Clin Invest"},{"issue":"44","key":"413_CR246","doi-asserted-by":"crossref","first-page":"34144","DOI":"10.1074\/jbc.M110.108100","volume":"285","author":"JJ Donkin","year":"2010","unstructured":"Donkin JJ, et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein\/presenilin 1 mice. J Biol Chem. 2010;285(44):34144\u201354.","journal-title":"J Biol Chem"},{"key":"413_CR247","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1750-1326-2-20","volume":"2","author":"I Lefterov","year":"2007","unstructured":"Lefterov I, et al. Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatment. Mol Neurodegener. 2007;2:20.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"413_CR248","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41598-018-36450-9","volume":"9","author":"JP Karjalainen","year":"2019","unstructured":"Karjalainen JP, et al. The effect of apolipoprotein E polymorphism on serum metabolome - a population-based 10-year follow-up study. Sci Rep. 2019;9(1):458.","journal-title":"Sci Rep"},{"issue":"3","key":"413_CR249","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.neuron.2013.07.033","volume":"79","author":"SC Ling","year":"2013","unstructured":"Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416\u201338.","journal-title":"Neuron"},{"issue":"5","key":"413_CR250","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ana.24493","volume":"78","author":"KA Josephs","year":"2015","unstructured":"Josephs KA, et al. TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. Ann Neurol. 2015;78(5):697\u2013709.","journal-title":"Ann Neurol"},{"issue":"5","key":"413_CR251","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ana.21154","volume":"61","author":"C Amador-Ortiz","year":"2007","unstructured":"Amador-Ortiz C, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol. 2007;61(5):435\u201345.","journal-title":"Ann Neurol"},{"issue":"11","key":"413_CR252","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1093\/brain\/aww224","volume":"139","author":"BD James","year":"2016","unstructured":"James BD, et al. TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. Brain. 2016;139(11):2983\u201393.","journal-title":"Brain"},{"issue":"Pt 5","key":"413_CR253","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/brain\/awr053","volume":"134","author":"PT Nelson","year":"2011","unstructured":"Nelson PT, et al. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain. 2011;134(Pt 5):1506\u201318.","journal-title":"Brain"},{"issue":"7-8","key":"413_CR254","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3109\/21678421.2014.918149","volume":"15","author":"F Govone","year":"2014","unstructured":"Govone F, et al. Lack of association between APOE gene polymorphisms and amyotrophic lateral sclerosis: a comprehensive meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7-8):551\u20136.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"2","key":"413_CR255","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/ene.13812","volume":"26","author":"A Canosa","year":"2019","unstructured":"Canosa A, et al. Correlation between Apolipoprotein E genotype and brain metabolism in amyotrophic lateral sclerosis. Eur J Neurol. 2019;26(2):306\u201312.","journal-title":"Eur J Neurol"},{"issue":"7","key":"413_CR256","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.ejhg.5200820","volume":"10","author":"P Verpillat","year":"2002","unstructured":"Verpillat P, et al. Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis. Eur J Hum Genet. 2002;10(7):399\u2013405.","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"413_CR257","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jalz.2012.10.013","volume":"9","author":"E Rubino","year":"2013","unstructured":"Rubino E, et al. Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: a meta-analysis. Alzheimers Dement. 2013;9(6):706\u201313.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"413_CR258","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/brain\/awx066","volume":"140","author":"A Mishra","year":"2017","unstructured":"Mishra A, et al. Gene-based association studies report genetic links for clinical subtypes of frontotemporal dementia. Brain. 2017;140(5):1437\u201346.","journal-title":"Brain"},{"issue":"3","key":"413_CR259","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/13554794.2012.667124","volume":"19","author":"KA Vossel","year":"2013","unstructured":"Vossel KA, et al. ApoE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease. Neurocase. 2013;19(3):295\u2013301.","journal-title":"Neurocase"},{"issue":"9","key":"413_CR260","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1474-4422(18)30251-5","volume":"17","author":"HS Yang","year":"2018","unstructured":"Yang HS, et al. Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE epsilon4 haplotype status: a community-based cohort study. Lancet Neurol. 2018;17(9):773\u201381.","journal-title":"Lancet Neurol"},{"issue":"1","key":"413_CR261","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"TF Outeiro","year":"2019","unstructured":"Outeiro TF, et al. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019;14(1):5.","journal-title":"Mol Neurodegener"},{"key":"413_CR262","doi-asserted-by":"crossref","unstructured":"Schweighauser M, et al. Structures of \u03b1-synuclein filaments from multiple system atrophy. Nature. 2020;585(7825):464\u20139.","DOI":"10.1038\/s41586-020-2317-6"},{"issue":"1","key":"413_CR263","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","volume":"14","author":"D Twohig","year":"2019","unstructured":"Twohig D, Nielsen HM. \u03b1-synuclein in the pathophysiology of Alzheimer's disease. Mol Neurodegener. 2019;14(1):23.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"413_CR264","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamaneurol.2013.600","volume":"70","author":"D Tsuang","year":"2013","unstructured":"Tsuang D, et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013;70(2):223\u20138.","journal-title":"JAMA Neurol"},{"issue":"12","key":"413_CR265","doi-asserted-by":"crossref","first-page":"e1182","DOI":"10.1212\/WNL.0000000000006212","volume":"91","author":"DW Dickson","year":"2018","unstructured":"Dickson DW, et al. APOE epsilon4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology. 2018;91(12):e1182\u201395.","journal-title":"Neurology"},{"issue":"11","key":"413_CR266","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/jnnp-2013-307228","volume":"85","author":"G Berge","year":"2014","unstructured":"Berge G, et al. Apolipoprotein E epsilon2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. J Neurol Neurosurg Psychiatry. 2014;85(11):1227\u201331.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"413_CR267","volume":"8","author":"CM Lill","year":"2012","unstructured":"Lill CM, et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet. 2012;8(3):e1002548.","journal-title":"PLoS Genet"},{"issue":"9","key":"413_CR268","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng.3043","volume":"46","author":"MA Nalls","year":"2014","unstructured":"Nalls MA, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014;46(9):989\u201393.","journal-title":"Nat Genet"},{"issue":"2","key":"413_CR269","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.nbd.2012.02.002","volume":"46","author":"M Federoff","year":"2012","unstructured":"Federoff M, et al. A large study reveals no association between APOE and Parkinson's disease. Neurobiol Dis. 2012;46(2):389\u201392.","journal-title":"Neurobiol Dis"},{"issue":"8","key":"413_CR270","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/archneur.62.8.1265","volume":"62","author":"LM de Lau","year":"2005","unstructured":"de Lau LM, et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study. Arch Neurol. 2005;62(8):1265\u20139.","journal-title":"Arch Neurol"},{"issue":"6","key":"413_CR271","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1212\/WNL.54.6.1272","volume":"54","author":"BS Harhangi","year":"2000","unstructured":"Harhangi BS, et al. APOE and the risk of PD with or without dementia in a population-based study. Neurology. 2000;54(6):1272\u20136.","journal-title":"Neurology"},{"issue":"12","key":"413_CR272","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1212\/WNL.55.12.1918","volume":"55","author":"HR Morris","year":"2000","unstructured":"Morris HR, et al. Multiple system atrophy\/progressive supranuclear palsy: alpha-Synuclein, synphilin, tau, and APOE. Neurology. 2000;55(12):1918\u201320.","journal-title":"Neurology"},{"issue":"4","key":"413_CR273","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/mds.27297","volume":"33","author":"K Ogaki","year":"2018","unstructured":"Ogaki K, et al. Multiple system atrophy and apolipoprotein E. Mov Disord. 2018;33(4):647\u201350.","journal-title":"Mov Disord"},{"key":"413_CR274","doi-asserted-by":"crossref","unstructured":"Davis AA, et al. APOE genotype regulates pathology and disease progression in synucleinopathy. Sci Transl Med. 2020;12(529):eaay3069.","DOI":"10.1126\/scitranslmed.aay3069"},{"key":"413_CR275","doi-asserted-by":"crossref","unstructured":"Zhao N, et al. APOE4 exacerbates alpha-synuclein pathology and related toxicity independent of amyloid. Sci Transl Med. 2020;12(529):eaay1809.","DOI":"10.1126\/scitranslmed.aay1809"},{"issue":"4","key":"413_CR276","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1176\/jnp.17.4.541","volume":"17","author":"T Freeman","year":"2005","unstructured":"Freeman T, et al. Neuropsychiatric associations of apolipoprotein E alleles in subjects with combat-related posttraumatic stress disorder. J Neuropsychiatry Clin Neurosci. 2005;17(4):541\u20133.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"10","key":"413_CR277","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/npp.2015.95","volume":"40","author":"LA Johnson","year":"2015","unstructured":"Johnson LA, et al. ApoE2 Exaggerates PTSD-Related Behavioral, Cognitive, and Neuroendocrine Alterations. Neuropsychopharmacology. 2015;40(10):2443\u201353.","journal-title":"Neuropsychopharmacology"},{"issue":"10153","key":"413_CR278","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, et al. Age-related macular degeneration. Lancet. 2018;392(10153):1147\u201359.","journal-title":"Lancet"},{"issue":"1","key":"413_CR279","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1086\/301901","volume":"63","author":"CC Klaver","year":"1998","unstructured":"Klaver CC, et al. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet. 1998;63(1):200\u20136.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"413_CR280","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","volume":"48","author":"LG Fritsche","year":"2016","unstructured":"Fritsche LG, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48(2):134\u201343.","journal-title":"Nat Genet"},{"issue":"4","key":"413_CR281","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/gim.2015.70","volume":"18","author":"JR Black","year":"2016","unstructured":"Black JR, Clark SJ. Age-related macular degeneration: genome-wide association studies to translation. Genet Med. 2016;18(4):283\u20139.","journal-title":"Genet Med"},{"issue":"40","key":"413_CR282","doi-asserted-by":"crossref","first-page":"13568","DOI":"10.1523\/JNEUROSCI.2468-15.2015","volume":"35","author":"O Levy","year":"2015","unstructured":"Levy O, et al. APOE Isoforms Control Pathogenic Subretinal Inflammation in Age-Related Macular Degeneration. J Neurosci. 2015;35(40):13568\u201376.","journal-title":"J Neurosci"},{"issue":"2","key":"413_CR283","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0304-3940(95)11353-3","volume":"187","author":"SM Pickering-Brown","year":"1995","unstructured":"Pickering-Brown SM, et al. Allelic variations in apolipoprotein E and prion protein genotype related to plaque formation and age of onset in sporadic Creutzfeldt-Jakob disease. Neurosci Lett. 1995;187(2):127\u20139.","journal-title":"Neurosci Lett"},{"issue":"7","key":"413_CR284","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1469-8749.2009.03476.x","volume":"52","author":"JA Blackman","year":"2010","unstructured":"Blackman JA. Apolipoprotein E genotype and cerebral palsy. Dev Med Child Neurol. 2010;52(7):600.","journal-title":"Dev Med Child Neurol"},{"issue":"12","key":"413_CR285","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/archneurol.2011.636","volume":"68","author":"C Bettencourt","year":"2011","unstructured":"Bettencourt C, et al. The APOE epsilon2 allele increases the risk of earlier age at onset in Machado-Joseph disease. Arch Neurol. 2011;68(12):1580\u20133.","journal-title":"Arch Neurol"},{"issue":"1-2","key":"413_CR286","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jns.2011.05.040","volume":"308","author":"C Xuan","year":"2011","unstructured":"Xuan C, et al. No association between APOE epsilon 4 allele and multiple sclerosis susceptibility: a meta-analysis from 5472 cases and 4727 controls. J Neurol Sci. 2011;308(1-2):110\u20136.","journal-title":"J Neurol Sci"},{"issue":"9","key":"413_CR287","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1136\/jmedgenet-2012-101175","volume":"49","author":"CM Lill","year":"2012","unstructured":"Lill CM, et al. Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects. J Med Genet. 2012;49(9):558\u201362.","journal-title":"J Med Genet"},{"issue":"2","key":"413_CR288","first-page":"108","volume":"36","author":"P Kehoe","year":"1999","unstructured":"Kehoe P, et al. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet. 1999;36(2):108\u201311.","journal-title":"J Med Genet"},{"issue":"12","key":"413_CR289","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1136\/jnnp.2003.022756","volume":"75","author":"C Saft","year":"2004","unstructured":"Saft C, et al. Apolipoprotein E genotypes do not influence the age of onset in Huntington's disease. J Neurol Neurosurg Psychiatry. 2004;75(12):1692\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"413_CR290","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00401-009-0501-8","volume":"118","author":"T Revesz","year":"2009","unstructured":"Revesz T, et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol. 2009;118(1):115\u201330.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"413_CR291","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ana.22516","volume":"70","author":"A Viswanathan","year":"2011","unstructured":"Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol. 2011;70(6):871\u201380.","journal-title":"Ann Neurol"},{"issue":"7","key":"413_CR292","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/00005072-199907000-00005","volume":"58","author":"MO McCarron","year":"1999","unstructured":"McCarron MO, et al. The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J Neuropathol Exp Neurol. 1999;58(7):711\u20138.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"6","key":"413_CR293","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/ana.410410607","volume":"41","author":"JA Nicoll","year":"1997","unstructured":"Nicoll JA, et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol. 1997;41(6):716\u201321.","journal-title":"Ann Neurol"},{"issue":"12","key":"413_CR294","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1212\/WNL.0000000000001398","volume":"84","author":"A Charidimou","year":"2015","unstructured":"Charidimou A, et al. Cerebral amyloid angiopathy with and without hemorrhage: evidence for different disease phenotypes. Neurology. 2015;84(12):1206\u201312.","journal-title":"Neurology"},{"key":"413_CR295","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.brainres.2008.10.036","volume":"1249","author":"F Gosselet","year":"2009","unstructured":"Gosselet F, et al. Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood-brain barrier: use of an in vitro model. Brain Res. 2009;1249:34\u201342.","journal-title":"Brain Res"},{"issue":"7693","key":"413_CR296","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature25739","volume":"554","author":"M Vanlandewijck","year":"2018","unstructured":"Vanlandewijck M, et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018;554(7693):475\u201380.","journal-title":"Nature"},{"issue":"39","key":"413_CR297","doi-asserted-by":"crossref","first-page":"11820","DOI":"10.1021\/bi026202k","volume":"41","author":"M Zeleny","year":"2002","unstructured":"Zeleny M, et al. Distinct apolipoprotein E isoform preference for inhibition of smooth muscle cell migration and proliferation. Biochemistry. 2002;41(39):11820\u20133.","journal-title":"Biochemistry"},{"issue":"5","key":"413_CR298","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1161\/01.STR.0000014774.88027.22","volume":"33","author":"D Woo","year":"2002","unstructured":"Woo D, et al. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke. 2002;33(5):1190\u20135.","journal-title":"Stroke"},{"issue":"8","key":"413_CR299","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1161\/STROKEAHA.112.659094","volume":"43","author":"HB Brouwers","year":"2012","unstructured":"Brouwers HB, et al. Apolipoprotein E genotype is associated with CT angiography spot sign in lobar intracerebral hemorrhage. Stroke. 2012;43(8):2120\u20135.","journal-title":"Stroke"},{"issue":"13","key":"413_CR300","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.2019.2413","volume":"321","author":"BA Gross","year":"2019","unstructured":"Gross BA, Jankowitz BT, Friedlander RM. Cerebral Intraparenchymal Hemorrhage: A Review. JAMA. 2019;321(13):1295\u2013303.","journal-title":"JAMA"},{"issue":"4","key":"413_CR301","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1056\/NEJM200001273420403","volume":"342","author":"HC O'Donnell","year":"2000","unstructured":"O'Donnell HC, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med. 2000;342(4):240\u20135.","journal-title":"N Engl J Med"},{"issue":"16","key":"413_CR302","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1212\/01.wnl.0000308819.43401.87","volume":"70","author":"C Tzourio","year":"2008","unstructured":"Tzourio C, et al. APOE genotype, ethnicity, and the risk of cerebral hemorrhage. Neurology. 2008;70(16):1322\u20138.","journal-title":"Neurology"},{"issue":"3","key":"413_CR303","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1212\/WNL.0b013e31829bfda4","volume":"81","author":"S Schilling","year":"2013","unstructured":"Schilling S, et al. APOE genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis. Neurology. 2013;81(3):292\u2013300.","journal-title":"Neurology"},{"issue":"6","key":"413_CR304","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.STR.31.6.1299","volume":"31","author":"Y Kokubo","year":"2000","unstructured":"Kokubo Y, et al. Age-dependent association of apolipoprotein E genotypes with stroke subtypes in a Japanese rural population. Stroke. 2000;31(6):1299\u2013306.","journal-title":"Stroke"},{"issue":"5","key":"413_CR305","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1227\/01.NEU.0000209605.18358.E5","volume":"58","author":"L Pawlikowska","year":"2006","unstructured":"Pawlikowska L, et al. Apolipoprotein E epsilon 2 is associated with new hemorrhage risk in brain arteriovenous malformations. Neurosurgery. 2006;58(5):838\u201343. discussion 838-43.","journal-title":"Neurosurgery"},{"issue":"9","key":"413_CR306","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-016-0361-4","volume":"30","author":"Y Yamazaki","year":"2016","unstructured":"Yamazaki Y, et al. Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence. CNS Drugs. 2016;30(9):773\u201389.","journal-title":"CNS Drugs"},{"issue":"6","key":"413_CR307","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.cell.2012.02.040","volume":"148","author":"Y Huang","year":"2012","unstructured":"Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148(6):1204\u201322.","journal-title":"Cell"},{"issue":"1","key":"413_CR308","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13024-020-0358-9","volume":"15","author":"T Williams","year":"2020","unstructured":"Williams T, Borchelt DR, Chakrabarty P. Therapeutic approaches targeting Apolipoprotein E function in Alzheimer's disease. Mol Neurodegener. 2020;15(1):8.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"413_CR309","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13024-018-0299-8","volume":"13","author":"J Cao","year":"2018","unstructured":"Cao J, et al. Advances in developing novel therapeutic strategies for Alzheimer's disease. Mol Neurodegener. 2018;13(1):64.","journal-title":"Mol Neurodegener"},{"key":"413_CR310","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13024-015-0001-3","volume":"10","author":"J Hu","year":"2015","unstructured":"Hu J, et al. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Abeta metabolism in apoE4-targeted replacement mice. Mol Neurodegener. 2015;10:6.","journal-title":"Mol Neurodegener"},{"issue":"6","key":"413_CR311","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2174\/1568026616666160617090227","volume":"17","author":"KP Koster","year":"2017","unstructured":"Koster KP, et al. Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOE. Curr Top Med Chem. 2017;17(6):708\u201320.","journal-title":"Curr Top Med Chem"},{"issue":"10","key":"413_CR312","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1194\/jlr.R075556","volume":"58","author":"M Moutinho","year":"2017","unstructured":"Moutinho M, Landreth GE. Therapeutic potential of nuclear receptor agonists in Alzheimer's disease. J Lipid Res. 2017;58(10):1937\u201349.","journal-title":"J Lipid Res"},{"issue":"6","key":"413_CR313","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.tem.2016.03.018","volume":"27","author":"R Courtney","year":"2016","unstructured":"Courtney R, Landreth GE. LXR Regulation of Brain Cholesterol: From Development to Disease. Trends Endocrinol Metab. 2016;27(6):404\u201314.","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"413_CR314","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrd4280","volume":"13","author":"C Hong","year":"2014","unstructured":"Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014;13(6):433\u201344.","journal-title":"Nat Rev Drug Discov"},{"issue":"19","key":"413_CR315","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1523\/JNEUROSCI.6546-10.2011","volume":"31","author":"D Terwel","year":"2011","unstructured":"Terwel D, et al. Critical role of astroglial apolipoprotein E and liver X receptor-\u03b1 expression for microglial A\u03b2 phagocytosis. J Neurosci. 2011;31(19):7049\u201359.","journal-title":"J Neurosci"},{"key":"413_CR316","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1326-5-44","volume":"5","author":"S Suon","year":"2010","unstructured":"Suon S, et al. Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid-\u03b2 peptides in the cerebral spinal fluid of rats. Mol Neurodegener. 2010;5:44.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"413_CR317","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3233\/JAD-132789","volume":"41","author":"NF Fitz","year":"2014","unstructured":"Fitz NF, et al. Improvement of memory deficits and amyloid-\u03b2 clearance in aged APP23 mice treated with a combination of anti-amyloid-\u03b2 antibody and LXR agonist. J Alzheimers Dis. 2014;41(2):535\u201349.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"413_CR318","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145467","volume":"10","author":"AG Sandoval-Hern\u00e1ndez","year":"2015","unstructured":"Sandoval-Hern\u00e1ndez AG, et al. Role of Liver X Receptor in AD Pathophysiology. PLoS One. 2015;10(12):e0145467.","journal-title":"PLoS One"},{"issue":"7","key":"413_CR319","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.neurobiolaging.2009.07.005","volume":"32","author":"T Vanmierlo","year":"2011","unstructured":"Vanmierlo T, et al. Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol Aging. 2011;32(7):1262\u201372.","journal-title":"Neurobiol Aging"},{"issue":"10","key":"413_CR320","volume":"14","author":"JM Mu\u00f1oz-Cabrera","year":"2019","unstructured":"Mu\u00f1oz-Cabrera JM, et al. Bexarotene therapy ameliorates behavioral deficits and induces functional and molecular changes in very-old Triple Transgenic Mice model of Alzheimer\u2019s disease. PLoS One. 2019;14(10):e0223578.","journal-title":"PLoS One"},{"issue":"1","key":"413_CR321","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11481-015-9627-8","volume":"11","author":"AW Corona","year":"2016","unstructured":"Corona AW, et al. ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP\/PS1 Mice. J Neuroimmune Pharmacol. 2016;11(1):61\u201372.","journal-title":"J Neuroimmune Pharmacol"},{"key":"413_CR322","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.nbd.2015.05.019","volume":"82","author":"I Lefterov","year":"2015","unstructured":"Lefterov I, et al. RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment. Neurobiol Dis. 2015;82:132\u201340.","journal-title":"Neurobiol Dis"},{"issue":"6135","key":"413_CR323","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1126\/science.1234089","volume":"340","author":"AR Price","year":"2013","unstructured":"Price AR, et al. Comment on \"ApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models\". Science. 2013;340(6135):924\u2013d.","journal-title":"Science"},{"issue":"1","key":"413_CR324","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12974-018-1091-y","volume":"15","author":"BT Casali","year":"2018","unstructured":"Casali BT, Reed-Geaghan EG, Landreth GE. Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease. J Neuroinflammation. 2018;15(1):43.","journal-title":"J Neuroinflammation"},{"key":"413_CR325","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2015.04.020","volume":"100","author":"E O'Hare","year":"2016","unstructured":"O'Hare E, et al. Lack of support for bexarotene as a treatment for Alzheimer's disease. Neuropharmacology. 2016;100:124\u201330.","journal-title":"Neuropharmacology"},{"issue":"2","key":"413_CR326","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3233\/JAD-150029","volume":"46","author":"C Balducci","year":"2015","unstructured":"Balducci C, et al. The Continuing Failure of Bexarotene in Alzheimer's Disease Mice. J Alzheimers Dis. 2015;46(2):471\u201382.","journal-title":"J Alzheimers Dis"},{"issue":"6135","key":"413_CR327","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1126\/science.1233937","volume":"340","author":"I Tesseur","year":"2013","unstructured":"Tesseur I, et al. Comment on \"ApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models\". Science. 2013;340(6135):924\u2013e.","journal-title":"Science"},{"issue":"6135","key":"413_CR328","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1126\/science.1235505","volume":"340","author":"K Veeraraghavalu","year":"2013","unstructured":"Veeraraghavalu K, et al. Comment on \"ApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models\". Science. 2013;340(6135):924\u2013f.","journal-title":"Science"},{"issue":"44","key":"413_CR329","doi-asserted-by":"crossref","first-page":"30538","DOI":"10.1074\/jbc.M114.600833","volume":"289","author":"LM Tai","year":"2014","unstructured":"Tai LM, et al. Amyloid-\u03b2 pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. J Biol Chem. 2014;289(44):30538\u201355.","journal-title":"J Biol Chem"},{"issue":"6135","key":"413_CR330","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1126\/science.1235809","volume":"340","author":"NF Fitz","year":"2013","unstructured":"Fitz NF, et al. Comment on \"ApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models\". Science. 2013;340(6135):924\u2013c.","journal-title":"Science"},{"issue":"2","key":"413_CR331","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.trci.2016.06.001","volume":"2","author":"K Ghosal","year":"2016","unstructured":"Ghosal K, et al. A randomized controlled study to evaluate the effect of bexarotene on amyloid-\u03b2 and apolipoprotein E metabolism in healthy subjects. Alzheimers Dement (N Y). 2016;2(2):110\u201320.","journal-title":"Alzheimers Dement (N Y)"},{"key":"413_CR332","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13195-016-0173-2","volume":"8","author":"JL Cummings","year":"2016","unstructured":"Cummings JL, et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease. Alzheimers Res Ther. 2016;8:4.","journal-title":"Alzheimers Res Ther"},{"key":"413_CR333","doi-asserted-by":"crossref","unstructured":"Loren J, et al. Liver X receptor modulators: a review of recently patented compounds (2009 - 2012). Expert Opin Ther Pat. 2013;23(10):1317\u201335.","DOI":"10.1517\/13543776.2013.814640"},{"issue":"44","key":"413_CR334","doi-asserted-by":"crossref","first-page":"14717","DOI":"10.1523\/JNEUROSCI.2053-15.2015","volume":"35","author":"J Kim","year":"2015","unstructured":"Kim J, et al. microRNA-33 Regulates ApoE Lipidation and Amyloid-\u03b2 Metabolism in the Brain. J Neurosci. 2015;35(44):14717\u201326.","journal-title":"J Neurosci"},{"issue":"6","key":"413_CR335","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cjca.2019.02.018","volume":"35","author":"A Hafiane","year":"2019","unstructured":"Hafiane A, Johansson JO, Genest J. ABCA1 Agonist Mimetic Peptide CS-6253 Induces Microparticles Release From Different Cell Types by ABCA1-Efflux-Dependent Mechanism. Can J Cardiol. 2019;35(6):770\u201381.","journal-title":"Can J Cardiol"},{"issue":"8","key":"413_CR336","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","volume":"20","author":"A Pickar-Oliver","year":"2019","unstructured":"Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019;20(8):490\u2013507.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"413_CR337","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262\u201378.","journal-title":"Cell"},{"issue":"1","key":"413_CR338","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13024-019-0343-3","volume":"14","author":"RWL So","year":"2019","unstructured":"So RWL, et al. Application of CRISPR genetic screens to investigate neurological diseases. Mol Neurodegener. 2019;14(1):41.","journal-title":"Mol Neurodegener"},{"issue":"6","key":"413_CR339","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","volume":"98","author":"YT Lin","year":"2018","unstructured":"Lin YT, et al. APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron. 2018;98(6):1141\u20131154.e7.","journal-title":"Neuron"},{"issue":"5","key":"413_CR340","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41591-018-0004-z","volume":"24","author":"C Wang","year":"2018","unstructured":"Wang C, et al. Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med. 2018;24(5):647\u201357.","journal-title":"Nat Med"},{"key":"413_CR341","doi-asserted-by":"crossref","first-page":"101349","DOI":"10.1016\/j.scr.2018.11.010","volume":"34","author":"B Schmid","year":"2019","unstructured":"Schmid B, et al. Generation of a set of isogenic, gene-edited iPSC lines homozygous for all main APOE variants and an APOE knock-out line. Stem Cell Res. 2019;34:101349.","journal-title":"Stem Cell Res"},{"issue":"39","key":"413_CR342","doi-asserted-by":"crossref","first-page":"10141","DOI":"10.1523\/JNEUROSCI.1054-16.2016","volume":"36","author":"C Lane-Donovan","year":"2016","unstructured":"Lane-Donovan C, et al. Genetic Restoration of Plasma ApoE Improves Cognition and Partially Restores Synaptic Defects in ApoE-Deficient Mice. J Neurosci. 2016;36(39):10141\u201350.","journal-title":"J Neurosci"},{"issue":"2","key":"413_CR343","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ana.24326","volume":"77","author":"KL Rasmussen","year":"2015","unstructured":"Rasmussen KL, et al. Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann Neurol. 2015;77(2):301\u201311.","journal-title":"Ann Neurol"},{"key":"413_CR344","doi-asserted-by":"crossref","unstructured":"Rasmussen KL, et al. APOE and dementia - resequencing and genotyping in 105,597 individuals. Alzheimers Dement. 2020. https:\/\/pubmed.ncbi.nlm.nih.gov\/32808727\/.","DOI":"10.1002\/alz.12165"},{"issue":"7","key":"413_CR345","volume":"3","author":"M Koch","year":"2020","unstructured":"Koch M, et al. Association of Apolipoprotein E in Lipoprotein Subspecies With Risk of Dementia. JAMA Netw Open. 2020;3(7):e209250.","journal-title":"JAMA Netw Open"},{"key":"413_CR346","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1326-9-11","volume":"9","author":"CW Medway","year":"2014","unstructured":"Medway CW, et al. ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. Mol Neurodegener. 2014;9:11.","journal-title":"Mol Neurodegener"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-020-00413-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13024-020-00413-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-020-00413-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T22:07:33Z","timestamp":1723846053000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-020-00413-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":346,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1186\/s13024-020-00413-4","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,4]]},"assertion":[{"value":"20 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been revised to include ORCIDs for all authors.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed to publish.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no competing of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}